NeuroTrauma Sciences (NTS) is a clinical-stage biopharmaceutical company dedicated to advancing treatments for stroke, specifically focusing on acute ischemic stroke (AIS) and chronic stroke. The company's lead compound, NTS-104, is currently in Phase 1 clinical trials, with plans for completion in 2025. NTS-104 is designed as a neuroprotective drug, which aims to mitigate the damage caused by strokes and improve patient outcomes. The company is also exploring next-generation candidates that can be administered via subcutaneous or intramuscular routes, targeting both acute and chronic stroke indications.

The leadership team at NeuroTrauma Sciences comprises seasoned professionals with extensive backgrounds in neuroscience, drug development, and regulatory affairs. Their expertise spans various aspects of biopharmaceutical development, including clinical operations, regulatory strategy, and commercialization. The team is committed to leveraging their collective experience to navigate the complexities of drug development, from preclinical research through to market authorization, with a strong emphasis on innovative approaches to treating neurological conditions.

United States

NeuroTrauma Sciences (NTS) is a biopharmaceutical company focused on developing therapies to treat the devastating effects of stroke and traumatic brain injury (TBI), including concussion. NTS is taking an innovative approach to the treatment of these conditions by addressing the fundamental underlying biological processes that enable the pathophysiological injury cascade.

NeuroTrauma Sciences

Company Details